AlphaMaven AlphaMaven
Private Equity

Water Street and JLL Partners’ Eversana announces acquisition of London’s Estima Scientific - PEI Private Equity

Reported by Privateequityinternational
Oct 30, 2026· 1 min read
Save Post LinkedIn Email
Key Takeaways
  • • Eversana, a portfolio company backed by Water Street and JLL Partners, has announced the acquisition of London-based Estima Scientific, according to PEI Private Equity.
  • • Estima Scientific is a health economics and outcomes research (HEOR) firm that combines specialist consulting with proprietary AI-powered software.
  • • The deal extends Eversana's health economics and outcomes capabilities in the UK, based on the announcement; financial terms were not disclosed in the source material.
Summary
Water Street and JLL Partners' Eversana has announced the acquisition of Estima Scientific, a London-based company, as reported by PEI Private Equity. The announcement positions the transaction as a strategic addition to Eversana's life sciences services platform.

Estima Scientific operates as a health economics and outcomes research (HEOR) company. Its model pairs specialist consulting services with proprietary AI-powered software, a combination aimed at supporting pharmaceutical and healthcare clients in evaluating the value of therapies and generating evidence for market access and reimbursement decisions.

The source material does not disclose the purchase price, deal structure, or the closing timeline. Readers seeking valuation or financing details should refer to the original announcement from Eversana or its sponsors.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Privateequityinternational Water Street and JLL Partners’ Eversana announces acquisition of London’s Estima Scientific - PEI Private Equity

Not a member yet?

Why AlphaMaven

The Alternative Investment
Intelligence Platform

Access nearly 1 million industry profiles in alternative investments — firms, funds, decision-makers and regulatory filings.

Start a free 7-day trial — card required, cancel anytime
Data · Intelligence · ROI
Company, fund & contact directory
Screener with filters & saved searches
Regulatory data — SEC, NFA, GLEIF, Form D
Manager-reported fund performance
11K+ members contributing data
Daily news with AI executive summaries
Data exports from your tracked list
Research guides, leaderboards & glossary
208,100+
Firms
615,900+
Decision-Makers
70,000+
Data Sources
Start your free 7-day trial

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.